Back to search

Netherlands· NL-453e940ced8a

Rezdiffra 60 mg filmomhulde tabletten

A resmetirom product containing resmetirom, registered in Netherlands by Madrigal Pharmaceuticals EU Limited. The same ATC class is registered in 9 of our 19 countries.

ATC A05BA11

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedRezdiffra 60 mg filmomhulde tablettenATCA05BA11REGISTER NO.NL-453e940ced8aPACKS LISTED1CHECKEDSeptember 29, 2026

Where it is registered

Resmetirom is registered in 9 of 19 countries.

Countries holding a registration under ATC A05BA11 (resmetirom), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 6 of them publish a price we can compare per daily dose

Resmetirom · ATC A05BA11

9 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
RESMETIROM
Manufacturer
Madrigal Pharmaceuticals EU Limited
Country
Netherlands (NL)
ATC code
A05BA11
ATC class
Resmetirom
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/25/1962

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/50788671-e44b-4dff-b898-120fdb6e8026
GET /v1/drugs/50788671-e44b-4dff-b898-120fdb6e8026?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmomhulde tablet",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/rezdiffra-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Resmetirom",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp133054",
  "excipients": [
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "CROSCARMELLOSE  NATRIUM  (E 468)",
    "MACROGOL 3350",
    "MAGNESIUMSTEARAAT (E 470b)",
    "MANNITOL (D-) (E 421)",
    "POLYVINYLALCOHOL (E 1203)",
    "SILICIUMDIOXIDE (E 551)",
    "TALK (E 553b)",
    "TITAANDIOXIDE (E 171)"
  ],
  "substances": [
    "RESMETIROM"
  ],
  "leaflet_url": null,
  "authorised_at": "2025/08/18",
  "procedure_number": "EMEA/H/C/006220",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/25/1962",
  "additional_monitoring": "Y"
}

See everything about resmetirom.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.